The MSD Animal Health Research Bursary for Veterinary Surgeons offers three awards, consisting of two ruminant bursaries and one companion animal bursary, of up to £4,000 each.
Each project should be completed within one to two years and the vet practitioner proposals will be judged by university academics to ensure independent assessment.
The companion animal research bursary will be assessed by the University of Nottingham Centre for Evidence-based Veterinary Medicine and the ruminant research bursary applications will be assessed by academic staff from the University of Bristol School of Veterinary Science.
Michelle Townley, veterinary advisor at MSD Animal Health (pictured right) said: "Our Vet Surgeon Research Bursaries have an important role to play in encouraging vet surgeons to continue to develop their research skills. New knowledge and good research skills form the life-blood of the industry so we’re keen to see proposals from both ruminant and companion animal practitioners. Being awarded a bursary has proved to be a career-changing experience for some participants so we’re keen to get as many applications as possible as part of our investment in the veterinary industry."
The deadline for entries is 30th November 2018. For more information, visit www.msdahresearchbursary.co.uk.
Sue, an RCVS and European Specialist in Veterinary Dermatalogy and Senior Vice President of the European Society of Dermatology, says the failure to prioritise pain relief is having a "profound effect on the quality of life of both dogs and clients."
Sue is urging vets to think about the impact that pain has on both the dog and owner in cases of OE: "Otitis externa is painful, it’s debilitating, and the degree of discomfort is often underestimated by both the veterinary surgeon and by the client."
Sue also says vets should not underestimate the owner’s concern about pain in their dog. Owners recognise the clinical signs associated with the pain of OE and determine treatment success by their dog recovering from these distressing symptoms.
To help manage the pain associated with OE, Sue recommends a multi-modal approach: "In addition to systemic pain relief, which is really important, a potent topical steroid is really useful to reduce the inflammation inside that dog’s ear, and make it much more comfortable."
Sue also highlights OE treatments which are able to coat the ear canal and stay there long enough to treat the pathogens and provide sustained pain relief: "When you put it into the ear, Osurnia Gel coats the lining of the external ear canal which gives prolonged contact with the lining of the canal to help treat the pathogens inside that dog’s ear."
Elanco says that despite Osurnia entering the market two years ago, some vets are still saving it for difficult cases. Sue said: "Too many vets use this [Osurnia] as a second-line drug and it should be used as a first-line product on the first occasion the dog comes through the door."
To watch the full series of videos and to find out more from Sue Paterson on treating otitis externa in dogs, visit: www.Osurnia.co.uk
1,300 veterinary surgeons responded to the BVA survey, which was carried out in July. They were asked what Official Controls Qualification (OCQ) they hold or have held in the past, and give reasons for dropping a previously held qualification or choosing not to revalidate.
According to the BVA, many respondents criticised the current training and revalidation process, which is administered by Improve International on behalf of the Animal and Plant Health Agency (APHA).
Factors including time, the cumulative cost of renewing each module at regular intervals, a lack of relevance and duplication of learning across different modules were all cited as reasons for choosing to drop qualifications.
25% of vets who currently hold the Essential Skills OCQ say they are planning not to renew the qualification, with 67% saying it is because of the expiry of grandfather rights and 66% saying it is because they find the requirements too onerous.
18% of those who currently hold the Tuberculin Testing OCQ are not planning on renewing, either because they are finding the revalidation requirements too onerous (58%), too expensive (42%) or because the work is not sufficiently rewarding (42%).
35% of those who hold the Statutory Surveillance OCQ are not planning on renewing, primarily because of overly onerous revalidation requirements.
The largest drop off is predicted amongst holders of the Exports OCQ, 38.4% of whom said they plan not to revalidate.
Amongst the species bolt-ons, 45.5% of the holders of the Small Animal Exports OCQ, 51% of the Ungulate Exports OCQ, 66% of the Equine Exports OCQ, 72.5% of the Avian Exports OCQ, 47% of the Product Exports OCQ, 68% of the Germinal Products Exports OCQ and 32% of the Companion Animals OCQ said they plan not to renew, either because of the expiry of grandfather rights, or the expense or, in the case of Ungulate Exports, because revalidation is too onerous.
In the current system equine exports are included in the ungulate export OCQ, which the BVA says was a concern for those vets who only work with farm animals. APHA and Improve International have helpfully introduced an equine-only OCQ for exports that better meets the needs of equine-only vets.
BVA reports that it has had a positive meeting with APHA to discuss the survey results and explore practical solutions to iron out issues with the current system and make it easier to use. As a next step, BVA has agreed to review the modules and make recommendations for improving the structure of training and the revalidation process.
BVA President John Fishwick said: "The unprecedented response rate to this survey really hits home the strength of feeling on this issue. There is an urgent need to review and improve the revalidation process to safeguard against capacity and capability issues in this critical section of the workforce.
"It’s really positive that APHA recognises that there are issues with the current system and is keen to work with us to make it more proportionate and fit for purpose while continuing to maintain high standards. It’s more important than ever to retain skilled professionals so that the workforce is at full strength to respond robustly to disease outbreaks and meet demand for export certification after Brexit."
Andrew Soldan, APHA Veterinary Director said: "The integrity of our official controls and export certification is vitally important. The Official Controls Qualifications are a key part of this as they provide standardised OV training as well as assurance of high standards. I’m grateful to BVA for their assistance as we look to make further improvements to the system in the future."
Your tip could be clinical in nature (perhaps specific to a particular discipline, like cardiology or exotics), or to do with practice management, or dealing with clients, or HR, or, well, anything really.
To enter the competition, login to VetSurgeon.org and submit your tip in the forum, here.
Just before you press the button to post your tip, you might like to tick the box marked: "EMAIL ME REPLIES TO THIS POST" which appears immediately above the post button. That way, you'll get an email when someone else posts a tip.
Above each post in the forum, there is now a 'Thank You' link, which allows members to express their thanks for sharing something. The five tips that generate the largest number of 'thank yous' by the end of November will win the Amazon vouchers.
VetSurgeon.org is all about facilitating the sharing of knowledge, ideas and experience. So any tip entered into the competition will also be disseminated, together with the contributor's name, on other social media channels, such as Facebook, Twitter, Linkedin and if you include a photo, on Instagram.
VetSurgeon.org Arlo Guthrie said: "The competition is really designed to show off the new 'thank you' feature on VetSurgeon, which allows members to show their appreciation when someone shares something useful with their peers. In due course, we'll be running similar competitions for the most thanked photos and videos uploaded to our galleries. Watch this space."
The online seminar, which equates to one hour’s CPD, features six UK experts in equine endocrinology, with the objective of supporting equine and mixed practice vets in using the clinical history to guide their interpretation of the basal ACTH test results and subsequent treatment decisions.
The speakers participating in the Equine Endocrine Pioneers Circle are:
Harry Carslake MA VetMB DipACVIM MRCVS: Senior lecturer in equine medicine at the University of Liverpool
Edd Knowles MA VetMB MVetMed DipECEIM MRCVS: Specialist in Equine internal medicine at Bell Equine Veterinary clinic
Professor Cathy McGowan BVSc DipVetClinStud MACVSc PhD DEIM DipECEIM FHEA MRCVS: Head of Department of Equine Clinical Science and Director of Veterinary Postgraduate Education at the University of Liverpool
Dr Nicola Menzies-Gow MA VetMB PhD DipECEIM Cert EM(Int Med) MRCVS: Reader in equine medicine at the Royal Veterinary College
Victoria South MA VetMB CertAVP(EM) DipECEIM MRCVS: Senior assistant at Liphook Equine Hospital
Nicola Steele BVM&S CertAVP(EM) MRCVS: Fyrnwy Equine Clinic and Director of Veterinary CPD (Equine and Large Animal)
The webinar considers when vets should test for PPID and decision-making on the best test to use, how to interpret grey zone results and also how to interpret problematic follow up tests. The experts have different opinions on some of these areas, allowing vets in practice to see the different ways in which cases can be viewed and managed.
These principles are then reinforced by the use of three clinical case scenarios with the patients all having the same basal ACTH result but a different selection of clinical signs.
Liz Barrett, equine business head at Boehringer Ingelheim said: "Since the launch of our Talk About Laminitis initiative in 2012, more than 50,000 horses have benefited from complimentary basal ACTH tests to aid the diagnosis of PPID, however two common areas of uncertainty in interpreting ACTH results still exist. Firstly, the interpretation of borderline, equivocal or ‘grey-zone’ results and when PPID treatment should or shouldn’t be recommended and secondly, the interpretation of follow-up ACTH test results and when to advise altering the treatment dose.
"The Equine Endocrine Pioneers Circle webinar allows vets to update their knowledge on this broad subject area and illustrates that there is often more than one way to approach the diagnosis, treatment and management of the PPID case."
To view the Equine Endocrine Pioneers Circle webinar on the Boehringer Academy visit https://www.boehringer-academy.co.uk/webinar/bil205
Working in collaboration with researchers at University of Texas, Southwestern (UTSW) Medical Center, the team has succeeded in using gene editing techniques on dogs to restore the expression of the dystrophin protein that is absent in DMD patients’ muscles to levels that could be life changing.
DMD is the most common, fatal, genetic disease that affects children. The same disorder also occurs in many dog breeds. It is caused by mutations in the gene that encodes dystrophin, a crucial protein that helps protect muscle fibres and the heart when they contract. Patients with the disease produce effectively no dystrophin protein, so their muscles and heart become damaged during contraction, leading to inability to walk, skeletal deformities, breathing problems and heart failure. Patients with DMD have a life expectancy that does not go far beyond their twenties.
Researchers say that this preliminary research, published in Science, demonstrates an approach that could lead to an effective, in principle one-time treatment for DMD for the most common genetic mutations affecting human patients. Through a single intravenous injection, researchers have been able to modify the dystrophin gene in many muscles of the body, including the heart, with the result that some muscles now had almost the normal amounts of dystrophin protein.
The team, led by Eric Olson, Ph.D., professor and chair of the Department of Molecular Biology at UTSW Medical Center and founder and chief science advisor of Exonics Therapeutics, and Richard Piercy, Ph.D., MRCVS, Professor of Comparative Neuromuscular Disease at the RVC, identified a naturally-occurring mutation in the dystrophin gene in a dog brought to the RVC’s Small Animal Referral Hospital.
Working now with relatives of this first dog, the combined group has used a technique called ‘SingleCut CRISPR gene editing’, where the researchers target a specific region of the subject’s own DNA. Harmless viruses encoding the gene-editing protein CRISPR/Cas9 were used to express the enzyme in muscle to cut the dogs’ own DNA at a precise location in the dystrophin gene through use of a molecular guide. The body’s own processes then repair the cut, which results in removing the negative effects of the existing mutation.
The researchers have demonstrated that dogs treated in this way had restored ability to produce large amounts of the dystrophin protein in their muscles and heart, and in the dog with the highest dose, cardiac muscles were found to have restored dystrophin protein to up to 92% of normal amounts after the single treatment.
The team believes this is the first time that this form of gene editing therapy has been conducted after birth in an animal larger than a rodent. With further longer-term research, efficacy and safety testing, it is hoped that this breakthrough will have human application. This treatment may be a significant step toward developing a gene editing therapy to repair genetic mutations for DMD, as well as a range of diseases caused by genetic mutations.
Richard Piercy, Professor of Comparative Neuromuscular Disease at the RVC, said: "Researchers have been looking for an effective and durable treatment for Duchenne muscular dystrophy for many years. This SingleCut gene editing approach, pioneered by Dr. Eric Olson’s group, has the potential to be a one-time treatment that could restore dystrophin protein. It is hugely exciting that through a single intravenous injection we’ve been able successfully to modify the dogs’ own DNA so they start generating dystrophin protein again. There is more work to be done, but with this exciting breakthrough, we feel we are a significant step closer to finding an effective treatment.
"A great many genetic diseases affect humans, dogs and other species - many, like DMD - with tragic consequences and this form of gene editing treatment might well be applicable in many of them. We’re hopeful that we’re paving the way for future research into treating some of the most serious genetic conditions that affect us today."
The aim of the competition is to highlight top tips for pet owners and the benefits of building a den to help calm and reassure dogs during the fireworks festivities.
Practices that want to take part in the in the competition need to post pictures of their dens and waiting rooms on the Ceva Animal Health Facebook page in October. The winning practice will receive a £200 voucher and there are 10 runner up prizes of luxury chocolate hampers.
Abigail King, behaviour product manager at Ceva Animal Health, said: "Our hugely popular fireworks display competition encourages veterinary practices to create eye-catching and imaginative displays that help educate pet owners on what can be done at home to help calm and reassure pets with firework fears."
Ceva has a range of marketing materials for veterinary practices to use in the competition, including waiting room materials.
For further information, contact your Ceva territory manager.
Alexander Reiter and Margherita Gracis formed the new editorial team and selected an international collection of leaders in their fields of expertise to contribute to this latest edition.
Alexander said: "This is a timely publication, as veterinary dentistry is a field that continues to grow in importance for the general veterinary practitioner. We found it important to add 'Oral Surgery' to this new edition, as many procedures performed in and around the mouth involve surgical techniques."
The BSAVA Manual of Canine and Feline Dentistry and Oral Surgery, 4th edition, is an accessible source of core information for general small animal veterinary surgeons, nurses/technicians and students interested in developing their theoretical knowledge and practical skills in dentistry and oral surgery.
The manual is now available from the BSAVA website (www.bsava.com/shop), the BSAVA Library (www.bsavalibrary.com/manuals), or by phone: 01452 726700.
Carl's article: 'Are you using a safety checklist in your practice?', focuses on the benefits of introducing a safety checklist in practice to reduce patient morbidity, mortality and to improve communication between members of the veterinary team.
He explains how a checklist helps eliminate the need to memorise every single step of a protocol and self-limit any errors that may eventually lead to a fatal or near-fatal incident, and how it should contain a limited number of elements, allow quick completion and most importantly be relevant to the situation.
The article includes information on how to introduce a safety checklist, steps to consider and how to use one in practice.
It also contains links to downloadable tools including the Association of Veterinary Anaesthetists (AVA) safety checklist and implementation booklet and information on the association’s ‘Safer Anaesthesia Project’. An editable safety checklist will also be available to download from the ‘Anaesthesia1ST’ blog that practices can adapt to their own requirements.
Richard Beckwith, country manager of Jurox (UK) said: "Our hugely popular Anaesthesia1ST newsletter features state-of-the-art, practical and easy to read articles to help veterinary professionals deliver 1ST class anaesthesia to all patients. Our latest edition will challenge practices to consider safety checklists as an essential part of their pre-anaesthetic routine in order to reduce the risk of mistakes."
To sign up to the Anaesthesia1ST newsletter visit the Alfaxan website – www.alfaxan.co.uk, contact your local Jurox technical sales representative or email Jurox at info@jurox.co.uk.
Moxiclear contains moxidectin and imidacloprid.
In dogs, Moxiclear can be used for the treatment and prevention of flea infestations and as part of a treatment plan for flea allergic dermatitis. It is also indicated for lungworm, ear mites, sarcoptes mites, biting lice, round worm, hookworm, whipworm, skinworm, and prevents heartworm.
In cats, Moxiclear can be used for the treatment and prevention of flea infestation and flea allergic dermatitis, as well as ear mite infestations. It is also indicated for notoedric mange, gastrointestinal nematodes; whipworm, roundworm and hookworm, and for the prevention of heartworm disease.
In ferrets, Moxiclear can be used to treat and prevent flea infestation, and prevent heartworm.
Moxiclear is available for 4kg-40kg dogs, with four pipette fill sizes. Small cats and ferrets weighing less than 4kg are catered for with a 0.4ml pipette. Large cats weighing 4-8kg can be treated with the Moxiclear 0.8ml pipette.
Lorron Bright, Norbrook Product Manager, said: "Moxiclear offers good value, broad-spectrum parasite control for dogs, cats and ferrets. This latest launch provides our customers with an excellent value, alternative choice for a imidacloprid/moxidectin product."
Richard Palmer, Norbrook Global Head of Sales and Marketing, said: "Moxiclear spot-on is the 11th product we have launched in the past three years. Six of the new products are in the companion animal sector as we continue to strengthen our foothold in the growing global companion animal market. Norbrook is committed to delivering a strong new product pipeline, along with our multi-year £50 million investment programme."
The extension includes a new diagnostic imaging suite with both CT and MRI scanners, a fourth operating theatre, two more consulting rooms, an additional ward for dogs and an expanded office for clinicians.
North Downs hospital director Terry Emmerson said: "This significant investment illustrates our commitment to providing the highest standards of medical and surgical care for our pets in a caring, compassionate environment.
"It has provided us with a number of important new facilities, allowing us to continue to build on our services and our level of care.
As part of the expansion, North Downs has also recruited five more clinicians, two specialising in small animal surgery, one in neurology, one in ophthalmology and one in anaesthesia.
Mr Emmerson said: "All the investment in facilities and technology is very important and exciting but we also recognised the need to invest in recruiting more talented staff to help us make the most of it all.
"That’s why we have added five new clinicians in several key disciplines and in turn increased the size of our clinicians’ office to help incorporate those additional staff.
"It all means we can now offer an even better service, leading facilities and treatment within a far more structured and organised layout which helps makes everything more efficient and user-friendly for staff and patients."
For more information about North Downs Specialist Referrals, visit www.ndsr.co.uk.
Dr Thomason initially denied both heads of charge, but on the third day of the hearing he changed his plea and admitted the charge in its entirety.
The first part of the charge related to the fact that the seller of the horse was a both a client of Dr Thomason’s practice and a personal friend of his, and he therefore had a potential and/or actual conflict of interest.
Dr Thomason did not disclose this professional and personal relationship to the prospective purchaser before the pre-purchase exam.
The prospective purchaser only discovered Dr Thomason’s relationship with the seller when reading the vetting certificate at home, and stated that, in the past, she had had a similar experience in which the horse was then found to be lame. She later found out the extent of the personal relationship, when invited to join the seller on a social media site.
The Committee found that, in this set of circumstances, Dr Thomason should not have undertaken the pre-purchase exam at all, and, at the very least, disclosed his personal and professional relationship with the vendor.
The Committee also found that although Dr Thomason did have a system in place to inform any prospective purchasers if the vendor was a client of his practice, this failed to work on this occasion and neither the practice nor Dr Thomason told the prospective buyer that the seller was a client before booking the pre-purchase exam. Dr Thomason had no similar system in place to disclose any close friendships with sellers.
Dr Thomason did not consider there was a conflict of interest as he felt confident he could carry out the pre-purchase exam impartially. In addition, it was his belief that the seller had been alerted to the conflict through a system in place at his practice, implemented to safeguard against this type of error. He stated that he in no way attempted to hide his relationship with the seller to the prospective purchaser.
It was not alleged that Dr Thomason had acted dishonestly.
Ultimately, the Committee found Dr Thomason not guilty of disgraceful conduct in a professional respect.
Ian Green, chairing the Committee and speaking on its behalf, said: "Whilst the Committee concluded that the respondent’s view of his obligations to disclose both the professional and personal relationships he had with the vendor was mistaken, it did not find any improper motivation on his part. It has already noted that he sought to disclose to the prospective purchaser through his system the fact that the vendor was a professional client of his.
"The Committee has weighed all these matters very carefully. It is for the client to determine whether or not to proceed with a PPE when in possession of all relevant facts in relation to any potential conflict of interest, and not for the veterinary surgeon to decide. The autonomy of the client must be respected. The Committee was firmly of the opinion that a failure to comply with the Code is very serious. However, taking into account the particulars of this case, the Committee does not consider that the actions of the respondent amount to disgraceful conduct in a professional respect."
Whilst the decision has been welcomed by the BVA and leading animal charities, it has not been entirely free of controversy. According to various reports, the Press Association has seen a letter from Defra to the Royal Veterinary College in February this year, which said the scientific studies it had commissioned were 'not strong enough to support a ban'.
Talking to the BBC, Ian Gregory, a lobbyist for pet collar manufacturers said that charities had also exaggerated the shock delivered by the collars, which at typically one millijoule is 1000 times less than cattle fencing. He argued that: "The anecdotal problems reported with pet collars can be resolved by product standards rather than by banning a proven technology".
The government has stopped short of banning invisible fencing systems which can keep pets away from roads, saying that the devices are particularly useful for cat owners and animals often respond well to invisible fencing and quickly learn to stay within a boundary without receiving a static pulse.
BVA President John Fishwick said: "As we review the latest evidence on the welfare impact of pulse pet containment fences, we would like to see them covered by a code of practice, as well as the regulation of the sale of these devices and manufacturer’s instructions, to ensure that the potential adverse effects of use are highlighted to animal owners and consumers."
Photo: Shutterstock
EnteroZoo is a dietary supplement composed of organic mineral and purified water in a gel suspension. Enteromed says it works by binding bacterial toxins as it passes through the animal's digestive tract, thereby helping to maintain a healthy gut and intestinal balance.
Enteromed says that compared to old classic adsorbents, such as clay or charcoal, EnteroZoo can be used long-term and is gentle on an animal's intestines.
The company points to a new in-vitro study from Brighton University School of Pharmacy & Biomolecular Sciences which has shown that EnteroZoo adsorbs E. coli, Shigella and C. difficile toxins1 – common causes of gastrointestinal infection and diarrhoea.
EnteroZoo is suitable for all animals including pregnant and nursing females. It is tasteless and odourless and the company says animals generally accept it without any problems. It can be administered in various ways: directly into the mouth, mixed into feed, put on a treat, mixed in an appropriate amount of water or administered with a plastic syringe into the oral cavity.
For more information, contact: enterozoo@enteromed.co.uk, or visit: www.enterozoo.co.uk
Reference
NOAH Chair Gaynor Hillier said: "The production and supply of veterinary medicines is totally dependent on complex international supply chains that must continue to function effectively after Brexit, their unique status being recognised in the recent government White Paper.
"Raw materials will need to arrive at manufacturing sites and veterinary medicines will need to be transported across borders to meet market requirements. Any border delays, additional complex processes or increased costs will risk medicines availability for UK vets, farmers and all our animals."
According to a recent NOAH member survey, less than 15% of companies say they are prepared for a 'hard Brexit' with the vast majority of respondents saying they are not fully prepared should there be a reversion to WTO rules on 30 March 2019.
NOAH says this is not through lack of effort or unawareness of the need to act, but due to the magnitude of the complex tasks involved in such a specialist sector, coupled with uncertainty over what a 'no-deal' Brexit will look like.
In contrast, almost 60% of companies said they are prepared for a transition period to December 2020. Even then, NOAH says the proposed transition period will not be enough in some cases.
The survey examined product availability in the UK: almost 55% of respondents reported potential availability issues for the UK market impacting more than 40% of their products. The full spectrum of types of products (from vaccines to painkillers: from antibiotics to wormers) across all animal species (farm, equine and pet) are potentially at risk, with particular concerns raised around the supply chain for vaccines.
Eurican Herpes is used to vaccinate pregnant bitches to prevent mortality, clinical signs and lesions in puppies from canine herpes virus infections acquired in the first few days of life, through passive immunity. It is the only canine herpes vaccine.
Humphrey Grimmett, Business Head for the pet prescription portfolio at Boehringer Ingelheim said: “We do understand how disruptive and frustrating it is when vaccines such as Eurican Herpes aren’t available to veterinary practices.
“We would like to reassure veterinary practices that we are doing everything we can behind the scenes to re-establish supply of Eurican Herpes, and we thank them for their support and patience.”
For further information, contact Boehringer’s Technical Services Team on 01344 746957 or email vetenquiries@boehringer-ingelheim.com.
The initiative will run until early 2019, and has been expanded to include cats as well as dogs. In the run up, Lintbells is also offering lunch and learn sessions to help practices implement the clinics.
The company reports that feedback from 50 veterinary surgeons, nurses and practice managers who took part in the initiative last year was encouragingly positive. 86% agreed or strongly agreed that they are now managing mobility issues more effectively in practice and 90% thought client compliance had increased.
96% said they thought vets, nurses and reception staff were communicating more effectively. 95% thought the training had improved staff morale. 94% of veterinary staff felt clients were more confident about managing their pet’s condition and 92% thought more mobility issues had been identified. 74% said they thought practice revenue had increased.
Lintbells Brand Manager, Gemma Cunningham said: "We’re really pleased to be able to help practices to provide support for pets with stiff joints. This year we’ve made some exciting additions to the practice pack based on our ongoing conversations and feedback. Mobility issues in cats are often overlooked and we want to raise awareness and help support owners. By including cats this time round we hope to assist practices with their efforts to encourage cat owners to have their less active and sedentary cats checked out."
Practices that want to register an interest in receiving a Mobility Matters pack can contact their local Lintbells Veterinary Business Development Executive or visit www.lintbellsvet.com.
Equitop GLME is a palatable, pearl formulation joint supplement developed to support the healthy function of cartilage, joint capsules, tendons and ligaments. It is derived from an active extract of New Zealand Green Lip Mussels - a natural source of glucosaminoglycans (GAGs), chondroitin and essential fatty acids – and is tested free of prohibited substances.
Boehringer says the nutrients in Equitop GLME help to lubricate joints, as well as supporting normal joint function, the stability and elasticity of ligaments and the shock-absorbing properties of cartilage.
Equitop GLME is fed once a day either separately or mixed with feed and one tub will typically last for 30 days and can be used in all horses and ponies.
Dr Amy Scott, brand manager for Equitop GLME at Boehringer Ingelheim, said: "By encompassing Equitop GLME into the Equitop portfolio and launching easy-to-read new packaging, we are enhancing our product offering to both veterinary practices and horse owners."
For more information, contact your Boehringer account manager.
Canine leishmaniosis is caused by the protozoan Leishmania infantum, which is found in most continents1. L. infantum is most commonly transmitted through the bite of sand flies and Bayer says there is a growing concern among parasitologists that the distribution of the disease is increasing due to climate change and more frequent pet travel.
Dr. Markus Edingloh, Head of Global Veterinary Scientific Affairs at Bayer Animal Health, said: "We are seeing more cases of canine leishmaniosis in areas where the disease had not previously been found. Dogs travelling and imported from endemic areas are of particular concern for introduction of the disease, while climate change is contributing to the spread of the vector.
It is therefore vital that veterinarians are aware of the disease and are recommending appropriate protection for dogs travelling to, or living in, endemic areas."
In dogs, there are a wide range of potential clinical signs associated with leishmaniosis including generalised lymphadenopathy, weight loss, lethargy, pyrexia, cutaneous lesions, ocular lesions and neurological or vascular disorders, while the severity of disease can vary from mild to life threatening2,3. In humans L. infantum tends to be responsible for the most severe form of leishmaniosis, visceral leishmaniasis, which can be fatal.
While distribution is worldwide, L. infantum is particularly prevalent in South America and the Mediterranean, with annual cases of zoonotic visceral leishmaniasis in people estimated to be 3,500 in Brazil and 875 in the Mediterranean1.
In some areas, over 80% of canine leishmaniosis cases may be asymptomatic1. However, the infection level in asymptomatic dogs is such that these dogs, in addition to the dogs showing clinical disease, can still be responsible for the spread of disease4. Therefore protection against infection to help control spread is vital for both human and dog health, as clinical cases will not always be obvious.
The non-profit scientific association, LeishVet, recommends that prevention should include the use of a long-acting topical insecticide throughout the period of sand fly activity: "Long-acting topical insecticides applied to dogs living in or travelling to endemic areas should be maintained during the entire risk period of potential exposure to/or activity of sand flies."
Bayer says that Seresto, which contains imidacloprid and flumethrin in a slow release collar, has been found to significantly reduce the risk of infection with Leishmania infantum in dogs for up to eight months. Three clinical field studies, performed in endemic areas, indicated a significant reduction in the risk of Leishmania infantum transmission by sand flies in treated dogs compared to non-treated dogs. The efficacy in the reduction of the risk of infection with leishmaniosis ranged from 88.3 to 100% 5,6,7.
For more information, visit www.vetcentre.bayer.co.uk/seresto.
References
Now, when you search Google for something which includes the word 'job' or 'jobs', Google presents an easy-to-filter list of local vacancies. You can also search in other locations.
One of the criteria for a job advert to be listed in Google for Jobs is that it must first have appeared on a webpage written with special code which allows the search engine to read the advert correctly.
VetSurgeon Jobs has been upgraded to include this code, and jobs advertised on VetSurgeon.org are now appearing on Google for Jobs.
VetSurgeon Editor Arlo Guthrie said: "We've known this was coming for some time, so we made sure VetSurgeon Jobs would be ready as soon as Google unveiled the new system.
"It has yet to be seen how widely Google for Jobs will be used by veterinary surgeons looking for a job. Back in the day, you'd have to wait for the latest copy of Vet Times to arrive in the post in order to find a job. Then came the internet, and with it a small handful of job websites worth checking for veterinary vacancies, of which VetSurgeon Jobs is one.
"Now, Google for Jobs provides one-stop search from most of the big players, although not all veterinary job boards are compatible with the new system and notably Indeed is excluded from Google for Jobs search results.
"The question now is whether jobseekers will continue to go directly to their favourite job website, or search Google first. Either way, though, you'll find jobs advertised on VetSurgeon.org!"
What do you think of the new Google for Jobs feature? Comment below.
The pack includes a new leaflet written by the dog behaviourist, Gwen Bailey, and supported by Blue Cross, Association of Pet Behaviour Counsellors (APBC), Wood Green, Puppy School, International Cat Care and Cats Protection.
The leaflet explains the signs of firework fears in both dogs and cats, how to keep pets calm and safe while fireworks are going off and the importance of ensuring that puppies become accustomed to loud and sudden noises gradually. It also highlights the benefits of pheromone support with Adaptil Calm Home Diffuser and Feliway CLASSIC Diffuser.
The company has also provided a leaflet holder, wall display, bunting and social media tool kit containing online banners, suggested social media posts, pet owner email text, PR and presentations.
Vouchers will be available for free Adaptil and Feliway for pet owners already purchasing product.
Abigail King, behaviour product manager at Ceva Animal Health said: "Our vibrant new fireworks marketing and display pack will help raise awareness of the signs of firework fears and the preventative measures that owners can carry out at home to help them keep their pets calm and safe during the fireworks season."
To request a copy of the fireworks marketing and display pack, contact your Ceva Animal Health territory manager or telephone 01494 781510.
Lynn Jo Ann Davies MRCVS first appeared before the Committee in January 2018 to face a number of charges related to two drink-driving offences, breaching the terms of her undertakings to the College as part of its Health Protocol, and being under the influence of alcohol on three occasions while she was on duty as a veterinary surgeon in December 2016.
Dr Davies admitted all five charges against her and admitted that this meant she was unfit to practise veterinary surgery and that she was guilty of disgraceful conduct in a professional respect. The Committee accepted her admissions and found, with the exception of one allegation, that her conduct was disgraceful in a professional respect.
At its first hearing the Committee having considered both aggravating and mitigating circumstances decided to postpone the hearing for six months on the basis of Dr Davies’ entering into a new set of undertakings, including one not to practise veterinary surgery and to remain abstinent from alcohol during the period of postponement.
At the second hearing, in July 2018, the Disciplinary Committee resumed its sanction inquiry decision. Dr Davies’ Counsel submitted on her behalf that Dr Davies wished to return to practise and the Committee reviewed her witness statements, documentary proof and medical records that she provided to demonstrate she had complied with the her undertakings given at the last hearing.
Stuart Drummond, Chairing the Committee and speaking on its behalf, said: "Having had the opportunity to see and hear from the respondent when she gave evidence and when she answered the questions put to her, the view formed of her current state of health was favourable. All members of the Committee considered that the account she gave of herself in the witness box was confident and they were reassured by her evidence as to how she now sets about managing her levels of stress and how she reacted to stressful incidents.
"Such concerns as the Committee had about her return to practice concerned her ability to receive support from a third party who would act as a mentor…the Committee therefore requires the Respondent to identify, within a period of one month of today’s date, a veterinary surgeon who would agree to act as her mentor. That mentor would have to be a veterinary surgeon acceptable to the College as someone suitable to act in that capacity and that mentor would have to be approved before the Respondent could resume practice.
"A further requirement of the Committee would be that the Respondent should make a disclosure to any new employer of the fact of her appearances before this Committee in January 2018 and in July 2018 and of the decisions of the Committee in relation to both such hearings. The final requirement of the Committee in this respect is that the respondent should not accept a 'sole charge position' at any time during her employment during this next period of postponement of sanction."
The Committee directed that the hearing be postponed for a further 12 months.
Comments received from students included: "They are an extremely supportive team that are very keen to teach and get the students involved at every opportunity" and: "They are very good at getting students involved and making them feel like part of the team".
Other winners included Fiona Ridout, pictured right, who won the award for the most engaged veterinary student on EMS placement. She had consistently excellent feedback across all her placements and significantly exceeded the RCVS required number of weeks for pre-clinical and clinical EMS. Feedback comments included: "Fiona has been highly motivated and reliable, always keen to help and gain experience"; "Fiona is one of the best students that we've have ever had"; 'Her clinical knowledge improves each time she visits", and: "Interactions from staff and clients have been impressive".
Golden Valley Vets in Nailsea Park, Bristol won the students’ award for most supportive veterinary nursing placement practice. Comments received from students included: "All the staff were really friendly, welcoming and patient and I left feeling like part of the team", and: "I was actively encouraged and supported with my Nursing Progress Log during my time there".
Megan Piper won the award for the most engaged veterinary nursing student on EMS placement. Megan received excellent feedback from her EMS placements and from her rotations. Feedback comments included: "When Megan qualifies she will make an excellent nurse and a very valued member of any team"; "Megan has consistently demonstrated a professional, motivated approach to her work in practice", and: "Our Referral Vets and Clinical Director were all very sad that she has finished her placement with us, and have invited her to come back once she has qualified".
Veronica Roberts, Senior Clinical Fellow in Equine Medicine at the University of Bristol said: "The University of Bristol believes that EMS prizes encourage and acknowledge student learning in a practical ‘real world’ situation, thus supporting the university in its aim to prepare graduates for day one competencies and life-long learning. We are grateful to practices for the invaluable contribution they make towards student education through offering EMS placements."
Wendy Talbot, National Equine Veterinary Manager at Zoetis said: "At Zoetis we are dedicated to supporting animal health through a wide range of quality medicines, vaccines, services and education so we are proud to sponsor these important prizes. They enable winning students to choose a preferred academic resource to help support them during their important first years in practice, while the winning practices can be formally thanked for their invaluable commitment and support."
The new chews incorporate Fr3sh technology, which Virbac says cleanses, cools and addresses the digestive causes of bad breath.
According to the company's research, the new chews provide significant daily breath improvement from Day 1 for a full 24 hours1, as well as continued breath improvement over a 2-week period. 90% of owners highlighted an improvement in bad breath following use of the chews1.
Virbac says the product is also scientifically proven to reduce calculus and plaque when given daily.2
Product Manager Claire Lewis said: "With 2 out of 3 pet owners having a least one dog with bad breath3, we are delighted to be able to add new VeggieDent Fr3sh to the Virbac range of oral healthcare products."
For more information, contact your Virbac Territory Manager.
References:
The BEVA has welcomed the news, whilst expressing its concern that the drug was suspended without consultation with the veterinary profession in the first place.
Jon Pycock, BEVA President said: "It remains a concern to BEVA that this mechanism was not put in place before the suspension of flunixin was imposed. Contrary to assertions by the VMD, wholesalers were unable to meet the demands of the veterinary profession and clinical use of this medicine was disrupted within 24 hours of the VMD’s initial announcement.
"We are surprised by the Regulator’s lack of awareness of availability in the supply chain and question why there was no consultation with the veterinary sector before the suspension was enacted. The VMD has been aware of this issue since March 2018 and it appears that no contingency was put in place to consider the animal welfare impact of this decision until it was too late."
BEVA Junior Vice President and Specialist in Equine Surgery Tim Mair continued: "Flunixin is a unique medicine in managing pain and sepsis in horses with colic. The VMD appeared to believe that this medicine could be substituted for other veterinary medicines and this is simply not the case. The release of stock from manufacturers is a short-term solution and, looking forward, we would like assurances that the VMD will fast track applications for the modification of product licenses to ensure that equine vets have continued access to these products."
Professor Kate White, Senior Vice President of the Association of Veterinary Anaesthetists added: "Provision of pain relief is essential to maintain animal welfare. The loss of these products would hinder the work of vets working with horses and donkeys and in zoos where they are first line drugs for the management of pain. Use of flunixin in these animals can be undertaken safely with no impact on human health."
Stock of flunixin held by manufacturers will be distributed alongside a ‘caution in use’ letter that will explain the restricted use of this product. BEVA is reminding all equine vets that the horse’s food chain status must be checked when using this product – either using the paper passport or the recently launched chip checker on the central equine database website.